The appointment coincides with the constitution of the Research Integrity Committee (CIR), chaired by the Ombudsperson and including different members of the IDIBELL research community, and the update of the “Guide to Good Practices in Research in Health Sciences”.
This 33rd edition, now virtual, has been organized by the professional team of the Cancer Epidemiology Research Program (IDIBELL-ICO) and by the IPVC.
A team from IDIBELL and ICO, using a mouse orthotopic model, conducted a real-time personalized oncology study to test the best therapeutic option to treat a type of relapse sarcoma.
Lung metastatic tumours have common immune properties, regardless of the origin of the primary tumour.
These results suggest new approximations and contemplate the development of new immunotherapy treatments.
Researchers from IDIBELL, the University of Göttingen and the University of Münster, designed six tables, using data available at the time of diagnosis, where easily extrapolate patient’s life expectancy.
The study has been published by the JAMA Surgery journal, the most prestigious in the world in its field, and has been led by Dr Sebastiano Biondo, from IDIBELL and the Bellvitge University Hospital.
The grant will go thyroid abnormalities research in rare childhood diseases.
By studying the role of lysosomes in mitosis, an IDIBELL and UB group discovers that alterations in the separation of chromosomes cause a detectable nucleus morphology once mitosis has finished. This morphology would be useful to identify cells that have chromosomal instability inherent in cancer cells.
Patients with this syndrome have more mutations in the microsatellite regions of the genome. The detection of these mutations improves the diagnosis and therapeutic management of patients.
The study, published in the Nature Communications journal, and led by the Netherlands Cancer Institute (NKI), has had the collaboration of researchers from IDIBELL/ICO and HUB.
This study demonstrates the beneficial effect of treatment with a cocktail drug at low doses to block a single signaling pathway in a lung cancer type.
